TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04639700

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psycho-educational intervention
Description: Participant will be sent a baseline survey, and will then be contacted by the interventionist to complete 4 sessions, which feature the following areas:~Session 1: Identifying CG Needs for Information \& Support, Communication with Healthcare Team~Session 2: Communication with Patient and Family~Session 3: Self-care: Emotional \& Spiritual Needs, Self-care: Physical Needs~Session 4: Re-Assessing Needs, Planning for the future
Study: NCT04575623

Intervention type: DIAGNOSTIC_TEST
Intervention: Duration Pattern test (DPT) /Dichotic Digits Test (DDT) /Auditory fusion test-revised (ART-R)/
Description: Central auditory function evaluation including:~* Duration Pattern test (DPT) designed to test temporal ordering abilities.~* Dichotic Digits Test (DDT) it assesses binaural integration skills.~* Auditory fusion test-revised (ART-R) to measure temporal resolution.~* speech in test to assess central auditory function.

Intervention type: DEVICE
Intervention: Dual band pure tone audiometer (Orbiter 992). -Impedance audiometer (AT 235h). -Sound treated booth (industrial acoustic company IAC model 1602-A-t) -Panasonic stereo CD player SA-AK 240.
Description: Cognitive function evaluation including:~-Recording of event-related potentials (ERPs) by using odd ball paradigm auditoryP300 wave in evaluating cerebral information processing.~Equipment:~* Dual band pure tone audiometer (Orbiter 992).~* Impedance audiometer (AT 235h).~* Sound treated booth (industrial acoustic company IAC model 1602-A-t)~* Panasonic stereo CD player SA-AK 240.
Study: NCT04336293

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: sTMS
Description: sTMS will be delivered following NeoSync guidelines using the device user~manual

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham sTMS
Description: sham sTMS will be delivered following NeoSync guidelines using the device user manual
Study: NCT05111886

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Survey of Experience
Description: Satisfaction with referral process

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Survey of Experience
Description: Satisfaction with referral process
Study: NCT05867303

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RC198 Injection
Description: RC198 injection will be administered subcutaneously on Day 1 of Week 1 to Week 4 (inclusive) of each 6-week (42-day) cycle.
Study: NCT05585060

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: the changes of end expiratory lung impedence
Description: the changes of end expiratory lung impedence measured by EIT

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: the changes of end expiratory lung volume
Description: the changes of end expiratory lung volume measured by apnea method
Study: NCT05307822

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Non-combusted cigarette variant 42001401
Description: Menthol flavor variant of a non-combusted cigarette (42001401)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Non-combusted cigarette variant 42001399
Description: Menthol flavor variant of a non-combusted cigarette (42001399)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Non-combusted cigarette variant 40007386
Description: Menthol flavor variant of a non-combusted cigarette (40007386)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Non-combusted cigarette variant 42001402
Description: Non-Menthol flavor variant of a non-combusted cigarette (42001402)
Study: NCT05830773

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resonance Breathing Exercises
Description: This intervention uses the Camera Heart Rate Variability (CHRV) smartphone application, a resonance breathing app that is available for download to iPhones and Android devices. The CHRV app uses Photoplethysmography (PPG) technology to measure heart rate. PPG is a noninvasive technology that uses a light source (the phone's flashlight) and a photodetector (the phone's camera lens) at the surface of one's skin to measure the volumetric variations of blood circulation. The app also has a timer (to allow the participant to see how long they use the app in each session). The iPhone version of the app also has a breathing pacer (a bar that moves up and down to show the participant when to inhale and exhale). Participants are instructed to initiate a resonance breathing session for at least 5 minutes every day and whenever they experience cravings, feel like they are going to relapse, feel anxious or stressed, or just want to feel calm.
Study: NCT06157463

Intervention type: RADIATION
Intervention: Ga-68 FAPI
Description: FAPI PET scans will be performed in addition to other staging/restaging work-up
Study: NCT05140668

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Comparison between Supraclavicular And Infraclavicular Approach For Ultrasound-Guided Right Subclavian Venous Catheterization
Description: Comparison between Supraclavicular And Infraclavicular Approach For Ultrasound-Guided Right Subclavian Venous Catheterization

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Comparison between Supraclavicular And Infraclavicular Approach For Ultrasound-Guided Right Subclavian Venous Catheterization
Description: Comparison between Supraclavicular And Infraclavicular Approach For Ultrasound-Guided Right Subclavian Venous Catheterization
Study: NCT06351696

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Bromlein
Description: 1500 mg/day

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (1500 mg/day)
Study: NCT04672395

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CpG 1018/Alum-adjuvanted SCB-2019 vaccine
Description: Group 1: Participants will receive 1 intramuscular (IM) injection of 30 microgram (ug) SCB-2019 with CpG1018/Alum adjuvant on Day 1 and on Day 22

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo; 0.9% saline
Description: Group 2: Participants will receive 1 IM injection of SCB-2019-matching placebo on Day 1 and on Day 22

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SCB-2019 vaccine
Description: Participants will receive 1 IM injection of 30 microgram (ug) SCB-2019 with CpG 1018/alum adjuvant

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: SCB-2019 vaccine for Placebo
Description: Participants will receive 2 IM injection of 30 microgram (ug) SCB-2019 with CpG 1018/alum adjuvant, 21 days apart
Study: NCT05708859

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tirzepatide
Description: Tirzepatide 15mg Subcutaneous Solution

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Volume matched Subcutaneous Solution
Study: NCT05208437

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Complete oral feeding intervention
Description: Premature infants will be assessed 12 times a day before feedings using the Feeding Preparation Scale by trained nurses. Assess the premature infants by using the Feeding Preparation Scale. If the premature infant does not meet the oral feeding standard, let the premature infant use the non-nutritive sucking for 3 minutes before the nasal feeding. If the premature infant meets the oral feeding standard, use the non-nutritive sucking for 3 minutes, and refer to the feeding schedule for the premature infant.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Routine nursing care group
Description: Pre-feeding assessments will be performed from premature infants corrected for gestational age at 34 weeks. If the baby's vital signs are stable, the method of oral feeding and then nasal feeding is used, and feeding 8 to 12 times a day until the baby reaches complete oral feeding.
Study: NCT06048029

Intervention type: PROCEDURE
Group type: OTHER
Intervention: laparscopic Cholecystectomy in children
Description: Evaluate preoperative and operative risk factors for conversion of laparoscopic cholecystectomy to open cholecystectomy

Intervention type: PROCEDURE
Group type: OTHER
Intervention: laparscopic Cholecystectomy in children
Description: Evaluate preoperative and operative risk factors for conversion of laparoscopic cholecystectomy to open cholecystectomy
Study: NCT05486845

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: survey
Description: We are planning a questionnaire survey. We combine our own questions with validated, official questionnaires. Validated forms ask for an assessment of the extent of low back pain and the quality of experienced stress.
Study: NCT04766216

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient self-management
Description: Patient makes independent decisions regarding warfarin therapy changes using warfarin dosing tools

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care provided by anticoagulation providers
Description: Normal care provided by anticoagulation providers
Study: NCT05095922

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Heart-Protecting Musk Pill
Description: Heart-Protecting Musk Pill (pill, 45mg, three times a day, 3 months)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Valsartan Capsules
Description: Valsartan Capsules(capsule, 80mg, once a day, 3 months）

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valsartan Capsules
Description: Valsartan Capsules(capsule, 80mg, once a day, 3 months）

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Calcium Dobesilate Capsules
Description: Calcium Dobesilate Capsules(capsule, 500mg, three times a day, 3 months)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcium Dobesilate Capsules
Description: Calcium Dobesilate Capsules(capsule, 500mg, three times a day, 3 months)
Study: NCT05922111

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: cervical ripening balloon for one hour
Description: The cervical ripening balloon will be left in place for one hour and after balloon removal the induction of labor will proceed at the discretion of the attending physician at labor and delivery room
Study: NCT05290337

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zanubrutinib
Description: BTK inhibitor
Study: NCT05708482

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sling-Swing Position
Description: The device is hammock which look likes a rope
Study: NCT05922111

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: cervical ripening balloon for twelve hours
Description: The cervical ripening balloon will be left in place for for twelve hours and after balloon removal the induction of labor will proceed at the discretion of the attending physician at labor and delivery room
Study: NCT03816488

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin (usual dose) administered 2 h before surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salsalate
Description: Salsalate 1.5 g administered 2 h before surgery
Study: NCT06311825

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Horticultural Therapy
Description: One week before horticultural therapy (HT) interventions, face-to-face interviews will be held with the individuals in the experimental group and the forms will be filled in as a pretest.~HT will be applied to the experimental group. The application period was determined as a total of 6 weeks with 50-minute sessions twice a week.~Before starting the HT sessions, area preparations will be made and a safe therapeutic garden will be established.~Medicinal and aromatic plants will be selected that can grow in Turkey, are not harmful to human health, are fragrant and colorful in order to stimulate the senses, and according to air temperature and physical conditions.~HT sessions will consist of gardening activities (group meeting, introduction of plants and cultivation).~After HT interventions, the forms will be filled as a post test. The forms will be filled again 4 weeks after the end of the interventions for follow-up.
Study: NCT05501275

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: psychotherapy
Description: Psychotherapy and psychoeducation in patients after stroke.
Study: NCT05823532

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Infliximab
Description: Infliximab has FDA approval for the treatment of rheumatoid arthritis and inflammatory bowel syndrome. The current proposal represents the use of infliximab as an experimental tool to dissect the role of inflammatory processes leading to changes in brain reward circuitry and changes in specific symptom domains.~Double-blinded infusions of infliximab will be administered in the GCTSA Clinical Research Center, located at Emory University Hospital. Independent pharmacists will dispense either infliximab or placebo in a 250ml saline bag according to a computer-generated randomization list provided by the study pharmacist.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Double-blinded infusions of saline will be administered in the GCTSA Clinical Research Center, located at Emory University Hospital. Independent pharmacists will dispense either infliximab or placebo in a 250ml saline bag according to a computer-generated randomization list provided by the study pharmacist.
Study: NCT06300827

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Structured digital-based training
Description: The eight week intervention will be delivered in 15 different sessions, each session lasting 40 minutes. It is expected that the seventh week session will last approximately 150 minutes. The control group is expected to continue with their daily lives.
Study: NCT05644756

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: IMPACT Methods to Identify and Prioritize Determinants (Challenge I), Challenge and Match strategies to Prioritized Determinants (Challenge II)
Description: IMPACT Center developed two methods for identifying determinants that involved providers, staff, and youth at community mental health centers in site visit 1: Rapid Ethnographic Assessment, Design Probes. Then, practice partners engage in a facilitated group activity to rate the criticality, chronicity, and ubiquity of the list of determinants in Site Visit 2. Finally, practice partners engage in a third site visit where they create Causal Pathway Diagrams that allow them to match strategies to prioritize determinants and create Implementation Plans.
Study: NCT04763109

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Whole-body Magnetic Resonance Imaging
Description: Whole-body Magnetic Resonance Imaging at baseline, 1 month, and 12 months
Study: NCT04637061

Intervention type: COMBINATION_PRODUCT
Intervention: intraoperative near infrared (NIR) indocyanine green (ICG)-induced fluorescence angiography (FA) and air leak testing to assess the integrity and the perfusion levels of the colorectal anastomosis
Description: Extra-luminal (serosa) and Endo-luminal (mucosal) evaluation of the proximal colon and distal rectal stump perfusion based on a semi-quantitative NIR-ICG-induced FA. This will be conducted administering IV a bolus of 3.75 to 7.5 mg of ICG and evaluated using a Fluorescence Imaging System; following after completion of the anastomosis a second bolos of 3.75 to 7.5 mg of ICG will be administered IV and the anastomosis will be visualized by insertion of the system trans-anally. Colon and rectal segments and quadrants will be scored for any defect of perfusion.

Intervention type: DIAGNOSTIC_TEST
Intervention: Air Leak test
Description: This will be conducted insufflaying air in the anastomosis through a proctoscope, tube or a flexible endoscope, after filling of the pelvis with saline solution and luminal occlusion of the intestine proximal to the anastomosis. Also, the anastomosis will be checked transanally for the presence of air leak.

Intervention type: DIAGNOSTIC_TEST
Intervention: Evaluation of the anastomotic rings
Description: The assessment of the anastomotic rings following mechanical anastomosis will be recorded as complete/incomplete
Study: NCT06563557

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hemodynamic changes between epidural and paravertebral during esophagectomy
Description: The thoracic epidural technique remains the gold standard for perioperative pain management for this procedure. The placement of a paravertebral catheter homolateral with the thoracic incisions is strongly recommended. A goal directed fluid therapy is proposed to guide fluid management and limit postoperative complications. Few studies suggested less side effects in the paravertebral group. The vasoplegia due to the epidural can cause significant hypotension especially as reverse Trendelenburg position is required during surgery. The aim is to bring more light to the hemodynamic changes caused by two different locoregional techniques. An algorithm for fluid and vasopressor management has been proposed. We defined hypotension as 20% of decrement of the median arterial pressure during anesthesia. To reduce bias, the locoregional techniques is performed by an experienced anesthesiologists and the rest of the perioperative management is conducted by another blinded anesthesiologist.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hemodynamic changes between epidural and paravertebral during esophagectomy
Description: The thoracic epidural technique remains the gold standard for perioperative pain management for this procedure. The placement of a paravertebral catheter homolateral with the thoracic incisions is strongly recommended. A goal directed fluid therapy is proposed to guide fluid management and limit postoperative complications. Few studies suggested less side effects in the paravertebral group. The vasoplegia due to the epidural can cause significant hypotension especially as reverse Trendelenburg position is required during surgery. The aim is to bring more light to the hemodynamic changes caused by two different locoregional techniques. An algorithm for fluid and vasopressor management has been proposed. We defined hypotension as 20% of decrement of the median arterial pressure during anesthesia. To reduce bias, the locoregional techniques is performed by an experienced anesthesiologists and the rest of the perioperative management is conducted by another blinded anesthesiologist.
Study: NCT06564766

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Debriefing
Description: In the experimental group, an expert instructor conducted a structured debriefing lasting about 10-15 minutes for each clinical scenario, while in the control group, no additional intervention was provided.~The debriefing used in this study has the following characteristics: brief (≤ 15 minutes), educator present, educator experienced in debriefing, focused on healthcare management or decision-making, and used the Plus-Delta method, where participants are asked to reflect on the simulation event and assess their performance by identifying what went well and areas for improvement.
Study: NCT06564064

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: abdominal binder
Description: study group will be abdominal binders and control group will be control group , 12 hrs and one week later VAS and QOR 40 will assess patient,s wellbeing

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: abdominal binder
Description: study group will be abdominal binders and control group will be control group , 12 hrs and one week later VAS and QOR 40 will assess patient,s wellbeing
Study: NCT05583955

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NOE-105
Description: Escalating dose levels of NOE-105 will be given and maximum tolerated dose will be maintained

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Escalating dose levels of matching Placebo will be given
Study: NCT05896371

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 177Lu-PSMA-I&T - escalating renal absorbed dose
Description: Personalized 177Lu-PSMA-I\&T injected activity

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 177Lu-PSMA-I&T - escalating renal absorbed dose
Description: Personalized 177Lu-PSMA-I\&T injected activity

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 177Lu-PSMA-I&T - escalating renal absorbed dose
Description: Personalized 177Lu-PSMA-I\&T injected activity

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 177Lu-PSMA-I&T - escalating renal absorbed dose
Description: Personalized 177Lu-PSMA-I\&T injected activity

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 177Lu-PSMA-I&T - escalating renal absorbed dose
Description: Personalized 177Lu-PSMA-I\&T injected activity

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 177Lu-PSMA-I&T - recommended phase 2 regime
Description: Personalized 177Lu-PSMA-I\&T injected activity

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 177Lu-PSMA-I&T - recommended phase 2 regime
Description: Personalized 177Lu-PSMA-I\&T injected activity

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 177Lu-PSMA-I&T - recommended phase 2 regime
Description: Personalized 177Lu-PSMA-I\&T injected activity

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 177Lu-PSMA-I&T - recommended phase 2 regime
Description: Personalized 177Lu-PSMA-I\&T injected activity

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 177Lu-PSMA-I&T - recommended phase 2 regime
Description: Personalized 177Lu-PSMA-I\&T injected activity
Study: NCT06563778

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chidamide; Decitabine; Anti-PD-1 Antibody
Description: Chidamide 10mg/day, day1-4; 20mg/day, day 8,11, 15, 18. Decitabine 10mg/day, day1-5. Physicians will decide which immune checkpoint inhibitors will be used during treatment.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Brentuximab Vedotin+ Bendamustine+Anti-PD-1 antibody
Description: Brentuximab Vedotin 1.2-1.8mg/kg day 1, Bendamustine 70-90mg/m2 day1-2, Anti-PD-1 antibody day 2. Physicians will decide which immune checkpoint inhibitors will be used during treatment.